Q-omics provides the consensus-scored IFNL3 profile across patient tissues and cancer cell-line models. IFNL3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, IFNL3 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, IFNL3 RNA expression shows 6,642 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, HNSC, and TGCT as cancer lineages where IFNL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNL3 survival associations across molecular data types. IFNL3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNL3 RNA expression–survival associations across cancer types. High IFNL3 expression shows unfavorable associations in UCEC, THYM, COAD, KIRC and LIHC, but favorable associations in ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for IFNL3 RNA expression.
This table summarizes IFNL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNL3 shows higher tumor expression in HNSC, LUAD, BRCA, LUSC, STAD and CHOL. The HNSC box plot shows higher IFNL3 RNA expression in tumor versus normal tissue (log2 FC = +0.118, t-test p < 0.001).
This table shows molecular features associated with IFNL3 in patient tissues and cancer cell lines. In patient samples, IFNL3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IFNL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
